ADVERTISEMENT
Dr Reddy’s Launches Anti-Epileptic Medicine In U.S. Market
The tablet is a generic equivalent of Lamictal ODT developed by GlaxoSmithKline group.
10 Oct 2016, 07:08 PM IST 
Tablets emerge from a tablet press at the pharmaceutical manufacturing facility (Photographer: Jonathan Drake/Bloomberg News)
Hyderabad-based pharmaceutical major Dr Reddy's Laboratories Ltd. launched orally disintegrating Lamotrigine tablets in the U.S. market.
The tablet is a generic equivalent of Lamictal ODT developed by GlaxoSmithKline group, the company said in a press release.
The drug is primarily used for treating epileptic seizures, mood swings in bipolar disorders and sometimes for cluster headaches and migraines.
The Lamictal ODT brand and generic had sales of around $65.5 million per annum in the U.S., as of July 2016. The generic version has been launched by Dr Reddy's in four variants of 25mg, 50mg, 100mg and 200mg, the release said.